adhesion G protein-coupled receptor E4, pseudogeneGenealiases: EMR4 · EMR4P · FIRE · GPR127 · PGR16
Q-omics provides the consensus-scored ADGRE4P profile across patient tissues and cancer cell-line models. ADGRE4P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADGRE4P is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ADGRE4P RNA expression shows 17,708 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where ADGRE4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRE4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRE4P survival associations across molecular data types. ADGRE4P RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRE4P RNA expression–survival associations across cancer types. High ADGRE4P expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in HNSC, SKCM and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADGRE4P RNA expression.
This table summarizes ADGRE4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADGRE4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRE4P shows lower tumor expression in LUSC and BRCA and higher tumor expression in KIRC, HNSC, THCA and KIRP. The KIRC box plot shows higher ADGRE4P RNA expression in tumor versus normal tissue (log2 FC = +0.584, t-test p < 0.001).
This table shows molecular features associated with ADGRE4P in patient tissues and cancer cell lines. In patient samples, ADGRE4P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRE4P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD.
